BCMA/TNFRSF17 Protein, Human (His & hFc), PE conjugated

BCMA/TNFRSF17 Protein, Human (His & hFc), PE conjugated is expressed in HEK293 mammalian cells with His and Fc tag. The accession number is NP_001183.2.

BCMA/TNFRSF17 Protein, Human (His & hFc), PE conjugated

パッケージサイズ	在庫状況	単価(税別)
25 μg	在庫あり	￥ 57,000
50 μg	約5 days	￥ 88,500
100 μg	約5 days	￥ 137,000
200 μg	約5 days	￥ 222,500

バルクのお問い合わせ

生物学的情報	Tested by Flow cytometric analysis of anti-BCMA CAR expression.
説明	BCMA/TNFRSF17 Protein, Human (His & hFc), PE conjugated is expressed in HEK293 mammalian cells with His and Fc tag. The accession number is NP_001183.2.

Species	Human
Expression Host	HEK293
Tag	His,Fc
Accession Number	NP_001183.2
別名	BCMA, TNFRSF13A, tumor necrosis factor receptor superfamily member 17, BCM, CD269
Construction	Recombinant human BCMA/TNFRSF17 (NP_001183.2, extracellular domain, Met 1-Ala 54) are conjugated with PE under optimum conditions, the unreacted PE was removed.

Formulation	Aqueous solution containing 0. 5% BSA and 0. 03%Proclin 300
Stability & Storage	This reagent is stable for 6 months from date of receipt when stored at 2℃ - 8℃. Protected from prolonged exposure to light. Do not freeze !
Shipping	Shipping at ambient temperature.
Research Background	Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.

参考文献

1. Novak AJ,et al.(2004) Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 103 (2): 689–94. 2. O'Connor BP,et al.(2004) BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 199(1): 91-8. 3. Moser K,et al.(2006) Stromal niches, plasma cell differentiation and survival. Curr Opin Immunol. 18(3): 265-70.

Calculator

Reconstitution Calculator

Recombinant Proteins Dilute Calculator

Specific Activity Calculator

bottom

BCMA/TNFRSF17 Protein, Human (His & hFc), PE conjugated

参考文献

Calculator

技術サポート

Keywords